Dare Bioscience Receives Nasdaq Delisting Notice Over Equity Shortfall
DARE sits 54% above its 52-week low of $1.27 on light trading volume (0.2× avg).
Summary
Dare Bioscience received a Nasdaq delisting notice on July 13, 2026, after its stockholders' equity fell below the required $2.5 million. The company plans to request a hearing to stay the delisting, but compliance is uncertain.
Key Events · Legal and Risk Events · DARE
-
Nasdaq Delisting Notice Received
On July 13, 2026, Nasdaq notified Dare Bioscience that it fails to meet the $2.5 million stockholders' equity requirement under Listing Rule 5550(b), based on its Q1 2026 10-Q.
-
Alternative Listing Standards Not Met
As of July 13, 2026, the company also does not satisfy the alternative requirements of $35 million market value of listed securities or $500,000 net income from continuing operations.
-
Hearing Request to Stay Delisting
Dare intends to timely request a hearing before a Nasdaq Hearing Panel, which will stay the suspension and delisting pending the panel's decision and any granted extension.
-
Compliance Uncertainty
There is no assurance the panel will grant an extension or that the company will regain compliance; failure to maintain listing could severely impact liquidity and capital access.
Analysis · DARE · Life Sciences
Dare Bioscience has been notified by Nasdaq that it no longer meets the minimum $2.5 million stockholders' equity requirement for continued listing. The company's Q1 2026 10-Q reported equity below that threshold, and as of July 13, 2026, it also fails the alternative tests of $35 million market value or $500,000 net income. While Dare intends to request a hearing — which temporarily stays delisting — there is no guarantee the panel will grant an extension or that the company can regain compliance. This comes just weeks after shareholders approved a 1.5 million share increase to the incentive plan and an $11.7 million capital raise, underscoring the urgency of its cash position. A delisting would severely impair liquidity and access to capital, threatening the commercial launch of its recently approved products.
At the time of this filing, DARE was trading at $1.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.4M. The 52-week trading range was $1.27 to $3.78. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.